Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma

Journal of Immunotherapy

Volumn 22, Issue 2, 1999, Pages 166-174

  Leong, Stanley P L ^a   Enders Zohr, Paula ^a   Zhou, Y M ^a   Stuntebeck, Susan ^a   Habib, Fahim A ^a   Allen, Robert E ^a   Sagebiel, Richard W ^b   Glassberg, Alan B ^c   Lowenberg, David W ^a   Hayes, F Ann ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AMGEN INC   (United States)

Author keywords

Active specific immunotherapy; GM CSF; Melanoma vaccine; Metastatic melanoma; Tumor regression

Indexed keywords

BCG VACCINE; CANCER VACCINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; HUMAN; MELANOMA; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; BCG VACCINE; CANCER VACCINES; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; MALE; MELANOMA; MIDDLE AGED; VACCINATION;

EID: 0033020036     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199903000-00008     Document Type: Article

References (32)

1. Oettgen HF, Old LJ. The history of cancer immunotherapy. In: Devita VT, Flellman S. Rosenberg SA. eds. Biological therapy of cancer. Philadelphia: JB Lippincott. 1991:87-119.
2. Barth A, Morton DL. Active specific immunotherapy of human melanoma. In: Leong SPL, ed. Immunotherapy of malignant melanoma. Austin, Texas: RG Landes. 1996:55-71.
3. Wallack M, Muthukumaran S. Whooley B, et al. Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial. Ann Sitrg Oncol 1995:3: 110-7.
4. Rosenberg SA, Lotze MT, Muul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987:316:889-97.
5. Rosenberg SA, Packard BS. Aebersold PM. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl. J Med 1988:319:1676-80.
6. Rosenberg SA. Immunotherapy with recombinant cytokines and activated lymphocytes in patients with advanced cancer: Review of Surgery Branch, NCI experience. In: Almon A, ed. Adjuvant therapy of cancer: Proceedings of the 6th International Conference on Adjuvant Therapy of Cancer. Philadelphia: WB Saunders, 1990:33-8.
7. Dranoff G, Jaffee E, Lazenby A. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993:90: 3539-43.
8. Dranoff G. Crawford AD, Sadelain M. et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994:264:713-6.
9. Johnson GR, Metcalf D. Detection of a new type of mouse eosinophil colony by Luxol-fast-blue staining. Exp Hematol 1980:8: 549-61.
10. Inaba K, Inaba M, Deguchi M, et al. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class Il-negative progenitor in mouse bone marrow. Proc Natl Acad Sei USA 1993:90:3038-42.
11. Metcalf D, Begley CG, Williamson DJ, et al. Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. Exp Hematol 1987:15:1-9.
12. Donahue RE, Wang EA, Stone DK, et al. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 1986;321:872-5.
13. Groopman JE, Mitsuyasu RT, DeLeo MJ, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987;317:593-8.
14. Morrisey PJ, Bressler L. Park LS, Alpert A. Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987:139:1113-9.
15. Witmar-Pack MD. Olivier W. Valinsky J. Schuler G, Steinman RM. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 1987;166:1484-98.
16. Collins HL. Bancroft GJ. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-a and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus ncoformans. Eitr J Immunol 1992:22:1447-54.
17. Weisbart RH. Kacena A, Schuh A, Golde DW. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 1988;332:647-8.
18. Fleishmann J. Golde DW. Weisbart RFI, Gasson JC. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 1986:68:708-11.
19. Silverstein DS. Owen WF. Gasson JC. et al. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol 1986:137:3290-4.
20. Weiser WY. Van Niel A. Clark SC, et al. Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages. J Exp Med 1987:166:1436-46.
21. Arnaou MA. Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases celI-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986:78: 597-601.
22. Weisbart RH, Golde DW, Gasson JC. Biosynthetic human GM-CSF modulates the number and affinity of neutrophil f-Met-Leu-Phe receptors. J Immunol 1986;137:3584-7.
23. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993;362:755-8.
24. Bukowski RM. Murthy S, McLain D. et al. Phase I trial of’recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunological effects. J Immunother 1993;13:267-74.
25. Laucius JF. Bodurtha AJ, Mastrangelo MJ, et al. A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic melanoma. Cancer 1977;40:2091-3.
26. Ber D, Maguire PM Jr. McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67.
27. Mitchel MS. Kan-Mitchell J, Kcmpf KA, Harel W, Shau H, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988:48: 5883-93.
28. Rib E, Cantrell J. Takayama K. Quereshi N, Peterson J. Ribi HO. Lipid A and immunotherapy. Rev Infect Dis 1984:6:567-72.
29. Mitchell MS, Harel W. Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-69.
30. Berd D, Maguire PM Jr. Mastrangelo MJ. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann NY Acad Sci 1993:147-52.
31. Ellem KAO, O’Rourke MGE. Johnson GR, et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997:44:10-20.
32. Area MJ, Krauss JC, Atsushi A, Cameron MJ. Shu S. Chang AE. Therapeutic efficacy of T cells derived from lymph nodes draining a Poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Thcr 1996;3:39-47.